Dupixent

Sep 12, 2025

COPD management has progressively centered on bronchodilator-based regimens, with Long-acting Muscarinic Antagonists (LAMAs) and Long-acting Beta-agonists (LABAs) forming the therapeutic core. Dual LAMA/LABA therapy is standard for moderate disease, while triple therapy with Inhaled Corticosteroids (ICS) is reserve...

Sep 01, 2025

Asthma: A Global Burden Driving Therapeutic Breakthroughs Asthma is a chronic inflammatory condition of the airways characterized by variable symptoms including wheezing, shortness of breath, chest tightness, and cough. It involves underlying airway inflammation, bronchial hyperresponsiveness, and reversible air...

Jul 01, 2025

Chronic urticaria is a persistent skin condition marked by recurrent, itchy wheals or hives that last for more than six weeks and can persist for over a year. As per DelveInsight’s analysts, approximately 4.7 million prevalent cases of chronic urticaria were reported across the 7MM in 2024, underscoring a significa...

Dec 20, 2024

Chronic obstructive pulmonary disease (COPD) is the third leading cause of death globally, according to the World Health Organization (WHO). It affects approximately 251 million people worldwide. Smoking is the leading cause of COPD, responsible for around 70-90% of cases. However, exposure to air pollution, occupa...

Oct 07, 2024

After more than ten years without significant therapeutic advancements in chronic obstructive pulmonary disease (COPD), patients with this progressive condition now have two new treatment options, with more likely to follow. Regeneron and Sanofi recently announced that the FDA has broadened the use of the highly...

Feb 27, 2024

Survodutide Phase II trial Shows Groundbreaking Results in Liver Disease due to MASH, with Significant Improvements in Fibrosis Boehringer Ingelheim has reported that in a Phase II trial, a significant proportion of adults treated with survodutide (BI 456906), up to 83.0%, showed a notable enhancement in metabol...

Feb 09, 2024

Sanofi and Regeneron are prioritizing pediatric care, particularly in their recent progress with the potent anti-inflammatory drug, Dupixent. On January 25, 2024, the FDA approved Dupixent, an IL-4 receptor alpha antagonist, for the treatment of eosinophilic esophagitis (EoE) in children aged 1 to 11, weighing at l...

May 31, 2023

DUPIXENT has shown positive pivotal results for COPD, confirming the key role of IL-4 and IL-13 in type 2 inflammatory diseases. DUPIXENT has the potential to be the first biologic with unprecedented and paradigm-shifting clinical results to treat COPD, having demonstrated a statistically significant reduc...

Sep 12, 2022

Key Highlights Tezspire (tezepelumab) with no phenotypic (eosinophilic or allergic) or biomarker restriction will be the new game-changer in the severe asthma marketDepemokimab is an excellent market replacement for GSKs’ Nucala as of its improved binding affinity and longer duration of action as a single doseNo...

May 24, 2022

EU Recommends Approval for PTC Therapeutics’ Gene Therapy Upstaza Upstaza, a gene therapy developed by PTC Therapeutics for patients with the genetic condition AADC deficiency, has been recommended for EU approval, putting another test of gene therapy's commercial prospects in the union. Upstaza (eladocagene exu...